Pyxis Oncology falls after wider-than-expected quarterly loss - PYXS News | RalliesPyxis Oncology falls after wider-than-expected quarterly loss
P
PYXS• Shares fall after Q2 loss miss
- Shares of cancer-drug developer Pyxis Oncology (PYXS.O) fell 1.5% to $3.13 in premarket trading.
- The company posted a Q2 loss of 40 cents per share, wider than analysts' average estimate of 35 cents per share, according to LSEG data.
- It reported no milestone revenue for the quarter, compared with $2.8 million a year earlier.
Expenses rise on severance and stock compensation
- General and administrative expenses rose to $9.9 million from $5.4 million, mainly due to higher severance costs and stock-based compensation.
- As of the last close, PYXS was up 176.5% year to date.
•
